uniQure shares plunged after four-year data for Huntington’s gene therapy AMT-130 showed weaker disease-progression slowing than earlier results. While 48-month TFC data remained encouraging, the cUHDRS effect was not statistically significant. Investors are now focused on FDA review and whether the therapy’s earlier benefits can demonstrate durability over time.